Distinctions in the binding sites of SMADs, STAT3, and c-SKI in the Smad3 promoter regions in cDCs and the HCC827 lung cancer cell line are consistent with the previous report showing that cell type–specific master transcription factors direct SMAD3 to distinct specific binding sites to determine cell type–specific responses to TGF-β signalling (Mullen et al, 2011). This evidence concerns the gene SMAD3 and lung carcinoma.